Results from a Meta-Analayses Evaluation Postoperative Chemoradiotherapy in Patients with Gastric Cancer with D2 Lymphadenectomy

Share this content:

the Cancer Therapy Advisor take:

The administration of adjuvant chemoradiotherapy after D3 lymphadenectomy in patients with gastric cancer is a controversial method of treatment.

Research from the Liaoning Cancer Hospital & Institute in Shenyang, China, that was recently published in the European Journal of Surgical Oncology, set out to perform a meta-analysis to analyze the safety and efficacy of postoperative chemoradiotherapy and determine the best practice for patients with gastric cancer in this category.

The researchers used PubMed, Cohrane, Web of Science and Ovid to perform a statistical analysis on STAT version 12.0 software. The researchers used Jadad and the Newcastle–Ottawa quality assessment scale to establish the quality of their evidence.  The researchers identified 2,135 patients who were involved in one of six studies and included the data from those patients in their meta-analysis.

According to the results of their research, postoperative adjuvant chemoradiotherapy produced a significant improvement in 5-year relapse-free survival (HR = 0.81, 95% CI 0.70–0.93, P = 0.004) and 5-year overall survival (HR = 0.79, 95% CI 0.68–0.92, P = 0.002) compared with patients who didn’t receive adjuvant chemoradiotherapy. There was no difference in treatment-related toxicity and distant metastasis (RR = 0.93, 95% CI 0.82–1.06, P = 0.304) between the groups.

The researchers concluded, based on their findings, that adjuvant chemoradiotherapy is associated with longer 5-year relapse-free survival and 5-year disease-free survival in patients with D2 lymphadenectomy. The researchers state that there is a need for additional comparative studies of with high-quality methodology in order to further evaluate this controversial treatment.

The Changing Landscape of Gastrointestinal Cancer Treatment
Adjuvant chemoradiotherapy is associated wither longer survival in patients with D2 lymphadenectomy.

The objective of the present meta–analysis was to analyze efficacy and safety of postoperative chemoradiotherapy (CRT) and establish a consensus on whether it is suitable for the patients.

From the results of the study, postoperative adjuvant CRT may be associated with longer 5–year overall survival (OS) and 5–year RFS in patients with D2 lymphadenectomy, but might not improve 5–year disease–free survival compared to non–CRT. Methodologically high–quality comparative studies are needed for further evaluation.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs